Major drugmaker Eli Lilly has agreed to acquire Versanis Bio, a privately held obesity drug maker, for up to $1.925 billion. The transaction is subject to customary...
Major drugmaker Eli Lilly is to pay up to $2.4 billion to acquire Dice Therapeutics, a US biotech specializing in developing oral medicines to treat chronic autoimmune...
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
Plans by major insulin producers Eli Lilly, NovoNordisk and Sanofi to drop their prices may be undercutting the US state of California’s state-backed generic insulin...
The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing...
Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price...
Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of...
As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly...
